Foundayo is the fastest new molecular entity approval since 2002

The FDA approved Foundayo (orforglipron), a once-daily GLP-1 pill for weight management, on April 1, 2026 — 50 days after the application was filed and 294 days before its scheduled decision date of January 20, 2027 ^[2]. The agency called it the fastest approval of a new molecular entity since 2002 and the first new molecular entity cleared under the Commissioner's National Priority Voucher (CNPV) pilot program ^[2].

The speed itself became the story. Foundayo was the fifth approval issued under CNPV, a program launched in 2025 to speed up applications the agency considers national health priorities ^[2]. As of the announcement, the FDA said it had awarded 18 vouchers and issued six decisions ^[2]. The program's stated tools are enhanced communication with the sponsor and rolling review, with a target decision timeline of two months and room for longer reviews when scientific reviewers decide more time is needed ^[2].

"By cutting idle time and maintaining constant communications with the company throughout the review process, we completed this national priority review with outstanding efficiency, while upholding the FDA's gold-standard science," FDA Commissioner Martin Makary said ^[2]. Acting Center for Drug Evaluation and Research Director Tracy Beth Høeg said the review team "delivered a thorough, high-quality product review and benefit-risk analysis, while simultaneously taking months off the standard filing-to-decision time" ^[2].

What was approved, and on what evidence

Foundayo is approved for use with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight plus at least one weight-related condition ^[2]. It is a GLP-1 receptor agonist tablet taken once daily, and the FDA noted it does not need to be taken on an empty stomach ^[2] — a contrast with Rybelsus, the oral form of semaglutide.

The label describes a stepwise dosing schedule starting at 0.8 mg, increasing to 2.5 mg after at least 30 days, then 5.5 mg after another 30 days, with possible further steps to 9 mg, 14.5 mg, or 17.2 mg after at least 30 days at each level, based on response and tolerability ^[2].

Two randomized, double-blind, placebo-controlled trials in adults with obesity or overweight plus one or more weight-related conditions supported the approval. After 72 weeks, people taking Foundayo had a statistically significant and clinically meaningful reduction in body weight compared with placebo ^[2]. The FDA press release did not publish the percentage weight loss figures, so the exact numbers behind the approval are not stated in these sources. A trade report listed specific trial registry numbers and enrollment counts ^[1], but those details are not confirmed in the FDA announcement.

Reported side effects include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, abdominal distension, fatigue, burping, reflux, gas, and hair loss ^[2]. Warnings cover pancreatitis, severe gastrointestinal reactions, acute kidney injury from volume depletion, low blood sugar, hypersensitivity, diabetic retinopathy in people with type 2 diabetes, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation ^[2]. The label carries a boxed warning for thyroid C-cell tumors and says the drug should not be used by people with a personal or family history of medullary thyroid cancer or with Multiple Endocrine Neoplasia syndrome type 2, or in combination with another GLP-1 receptor agonist ^[2].

Why it matters for patients

A faster review means a new option reaches pharmacies sooner, but it also means less time between filing and approval for outside scrutiny of the data. The FDA says safety was not compromised and that rolling review and constant contact with the sponsor removed idle time rather than review steps ^[2].

Practically, the approval adds an oral daily tablet to a category dominated by weekly injections such as Wegovy (semaglutide) and Zepbound (tirzepatide) ^[1]. Price, insurance coverage, and supply were not addressed in the FDA announcement and are not yet known from these sources.

The sources also disagree on timing details: the FDA lists the application's PDUFA date as January 20, 2027 ^[2], while a trade tracker listed a July 12, 2026 PDUFA target ^[1].

What happens next

The FDA scheduled a public meeting on June 4, 2026 (moved up from June 12) to take feedback on the CNPV program's eligibility criteria, voucher selection, sponsor responsibilities, review procedures, and implementation ^[2]. Written comments are open through June 29, 2026 ^[2].